MedTrace Logo

Efficiency and Safety a Fixed Combination of Orphenadrine and Diclofenac for Postoperative Analgesia

NCT05322603 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-08-22

No results posted yet for this study

Summary

The study will include 60 patients after cardiac surgery. The first group will include 30 patients who will use the drug Neodolpasse manufactured by Fresenius Kabi, which is a fixed combination of 30 mg of orphenadrine and 75 mg of diclofenac; the second group will consist of 30 patients who will use patient-controlled morphine analgesia (РСА) in the form of monotherapy.

Conditions

  • Analgesia

Interventions

DRUG

Analgesics Non Opioid (Neodolpasse manufactured by Fresenius Kabi)

A decrease in the pain severity (VAS);opioid-sparing effect

DRUG

Analgesics

A decrease in the pain severity (VAS)

Sponsors & Collaborators

  • Petrovsky National Research Centre of Surgery

    lead OTHER

Principal Investigators

  • Alexander A. Eremenko, prof · Head of the Intensive Care Unit

  • Lyubov S. Sorokina · anesthesiologist-resuscitator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-18
Primary Completion
2022-08-20
Completion
2022-08-20

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05322603 on ClinicalTrials.gov